TFX — Teleflex Incorporated

Is TFX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of October 3, 2026

Teleflex Incorporated (TFX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $124.12. The rating moved from Neutral to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Teleflex is a diversified medical-device company with a strong mix of recurring consumables and clinician-preferred products that drive steady cash flow. Its portfolio exposure to anesthesia, vascular access and respiratory segments provides resilience versus single-category peers and supports margin durability. Near-term catalysts include recovery in procedure volumes, successful integration of bolt-on acquisitions and stable pricing in specialized disposables. Key challenges are elective procedure sensitivity, supply-chain and input-cost pressure, competitive dynamics and potential regulatory/recall risk. Given current market caution and healthcare device sector headwinds, performance over the next month will likely be driven by procedure trends, FY guidance clarity and any incremental operational updates.

Key factors

  • Diversified medical-device portfolio with recurring consumables (anesthesia, respiratory, vascular access, urology) supporting stable revenue streams
  • Strong cash generation historically enabling reinvestment, bolt-on M&A and share repurchases
  • Exposure to secular trends (aging population, chronic disease management, procedural growth) supporting mid-term demand
  • Aftermarket and recurring revenue mix cushions cyclical swings in capital spending
  • Reasonable pricing power in specialized disposable products and clinician-preferred device categories
  • Relatively stable margin profile versus broader healthcare discretionary segments

Risks

  • Near-term sensitivity to elective procedure volumes if macro risk aversion or hospital budgets tighten
  • Supply-chain disruption and input-cost inflation that could compress margins or force price concessions
  • Intense competition from larger device OEMs and private-label suppliers driving price pressure in commoditized product lines
  • Regulatory, recall or litigation events that can hit sales and increase costs in device businesses
  • Foreign-exchange exposure and geopolitical uncertainty that can depress overseas sales and margins
  • Reimbursement pressure and hospital purchasing consolidation that can reduce unit pricing or reorder cadence

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TFX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.